Regeneron Drug Cuts Muscle Loss With Semaglutide
Regeneron reported its experimental drug trevogrumab halved muscle mass loss when combined with Novo Nordisk weight loss treatment semaglutide in an obesity trial. The combination preserved lean mass effectively, addressing key concerns over muscle degradation during rapid weight loss.
Xurve View
Insights:
Xurve View
An experimental weight-loss drug developed by REGENERON PHARMACEUTICALS combined with NOVO NORDISK A/S-B's semaglutide cut muscle mass loss by 50% in a study of nearly 1,000 obesity patients.
